Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
66 hedge funds and large institutions have $214M invested in Aptose Biosciences, Inc. in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 14 closing their positions.
439% more call options, than puts
Call options by funds: $2.49M | Put options by funds: $463K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
3% more funds holding
Funds holding: 64 → 66 (+2)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
23% less capital invested
Capital invested by funds: $278M → $214M (-$64.7M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$37.2M |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$19.7M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.12M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$48M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.41M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.22M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$3.5M |
APTO Hedge Fund Activity: Q4 2020 in Review
66 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2020, worth a combined $214M — down 23% from $278M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new APTO positions and 14 closed out — a net gain of 4 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was OrbiMed, adding an estimated $37.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $48M sold.
- 66 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2020, up from 64 in Q3 2020.
- Funds reported $214M of Aptose Biosciences, Inc. stock for Q4 2020, down 23% quarter-over-quarter.
- 18 funds opened new Aptose Biosciences, Inc. positions in Q4 2020 and 14 closed out, a net change of +4 holders.
- The largest Aptose Biosciences, Inc. buyer in Q4 2020 was OrbiMed, an estimated $37.2M added.
- The largest Aptose Biosciences, Inc. seller in Q4 2020 was Consonance Capital Management, an estimated $48M sold.
Based on aggregated 13F filings for Q4 2020.